Business Description
Jafron Biomedical Co Ltd
ISIN : CNE100002995
Share Class Description:
SZSE:300529: Class ACompare
Compare
Traded in other countries / regions
300529.China IPO Date
2016-08-02Description
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.68 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.49 | |||||
| Debt-to-EBITDA | 1.56 | |||||
| Interest Coverage | 16.65 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 8.51 | |||||
| Beneish M-Score | -2.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.4 | |||||
| 3-Year EBITDA Growth Rate | -12.3 | |||||
| 3-Year EPS without NRI Growth Rate | -19.6 | |||||
| 3-Year FCF Growth Rate | 5.7 | |||||
| 3-Year Book Growth Rate | 3.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 57.28 | |||||
| Future 3-5Y Total Revenue Growth Rate | 37.77 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.17 | |||||
| 9-Day RSI | 36.2 | |||||
| 14-Day RSI | 41.45 | |||||
| 6-1 Month Momentum % | 8.82 | |||||
| 12-1 Month Momentum % | 37.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.77 | |||||
| Quick Ratio | 3.41 | |||||
| Cash Ratio | 3.11 | |||||
| Days Inventory | 243.46 | |||||
| Days Sales Outstanding | 11.64 | |||||
| Days Payable | 99.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.36 | |||||
| Dividend Payout Ratio | 0.39 | |||||
| 3-Year Dividend Growth Rate | 12.2 | |||||
| Forward Dividend Yield % | 1.36 | |||||
| 5-Year Yield-on-Cost % | 5.58 | |||||
| 3-Year Average Share Buyback Ratio | -0.4 | |||||
| Shareholder Yield % | 0.93 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.74 | |||||
| Operating Margin % | 39.21 | |||||
| Net Margin % | 30.56 | |||||
| FCF Margin % | 33.15 | |||||
| ROE % | 25.43 | |||||
| ROA % | 14.39 | |||||
| ROIC % | 31.52 | |||||
| ROC (Joel Greenblatt) % | 57.62 | |||||
| ROCE % | 22.38 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 30.34 | |||||
| Forward PE Ratio | 17.05 | |||||
| PE Ratio without NRI | 29.6 | |||||
| Shiller PE Ratio | 38.55 | |||||
| Price-to-Owner-Earnings | 51.25 | |||||
| PEG Ratio | 2.87 | |||||
| PS Ratio | 9.24 | |||||
| PB Ratio | 7.3 | |||||
| Price-to-Tangible-Book | 7.56 | |||||
| Price-to-Free-Cash-Flow | 27.8 | |||||
| Price-to-Operating-Cash-Flow | 20.18 | |||||
| EV-to-EBIT | 21.63 | |||||
| EV-to-EBITDA | 21.63 | |||||
| EV-to-Revenue | 8.54 | |||||
| EV-to-FCF | 26.36 | |||||
| Price-to-Projected-FCF | 2.58 | |||||
| Price-to-DCF (Earnings Based) | 0.96 | |||||
| Price-to-DCF (FCF Based) | 0.89 | |||||
| Price-to-Graham-Number | 3.15 | |||||
| Price-to-Net-Current-Asset-Value | 24.25 | |||||
| Price-to-Net-Cash | 58.96 | |||||
| Earnings Yield (Greenblatt) % | 4.62 | |||||
| FCF Yield % | 3.63 | |||||
| Forward Rate of Return (Yacktman) % | 0.31 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jafron Biomedical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 2,632.057 | ||
| EPS (TTM) (Â¥) | 0.991 | ||
| Beta | 1.57 | ||
| Volatility % | 48.73 | ||
| 14-Day RSI | 41.45 | ||
| 14-Day ATR (Â¥) | 0.81409 | ||
| 20-Day SMA (Â¥) | 30.146 | ||
| 12-1 Month Momentum % | 37.08 | ||
| 52-Week Range (Â¥) | 15.88 - 39.24 | ||
| Shares Outstanding (Mil) | 798.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jafron Biomedical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jafron Biomedical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Jafron Biomedical Co Ltd Frequently Asked Questions
What is Jafron Biomedical Co Ltd(SZSE:300529)'s stock price today?
The current price of SZSE:300529 is ¥30.07. The 52 week high of SZSE:300529 is ¥39.24 and 52 week low is ¥15.88.
When is next earnings date of Jafron Biomedical Co Ltd(SZSE:300529)?
The next earnings date of Jafron Biomedical Co Ltd(SZSE:300529) is .
Does Jafron Biomedical Co Ltd(SZSE:300529) pay dividends? If so, how much?
The Dividend Yield %  of Jafron Biomedical Co Ltd(SZSE:300529) is 1.36% (As of Today), Highest Dividend Payout Ratio of Jafron Biomedical Co Ltd(SZSE:300529) was 1.24. The lowest was 0.34. And the median was 0.47. The  Forward Dividend Yield % of Jafron Biomedical Co Ltd(SZSE:300529) is 1.36%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers